Nika Pharmaceuticals, Inc.
NIKA
$0.32
-$0.16-32.66%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 200.00 | 200.00 | 200.00 | 200.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 200.00 | 200.00 | 200.00 | 200.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 52.20K | 56.30K | 89.40K | 84.20K | 85.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.20K | 56.30K | 89.40K | 84.20K | 85.90K |
| Operating Income | -52.20K | -56.30K | -89.40K | -84.20K | -85.90K |
| Income Before Tax | -52.20K | -56.30K | -89.40K | -84.20K | -85.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.05 | -0.06 | -0.09 | -0.08 | -0.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.20K | -56.30K | -89.40K | -84.20K | -85.90K |
| EBIT | -52.20K | -56.30K | -89.40K | -84.20K | -85.90K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 4.10B | 4.09B | 3.94B | 3.79B | 3.65B |
| Average Diluted Shares Outstanding | 4.10B | 4.09B | 3.94B | 3.79B | 3.65B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |